OUP user menu

Hormone therapy and risk of myocardial infarction: a national register study

Ellen Løkkegaard, Anne Helms Andreasen, Rikke Kart Jacobsen, Lars Hougaard Nielsen, Carsten Agger, Øjvind Lidegaard
DOI: http://dx.doi.org/10.1093/eurheartj/ehn408 First published online: 30 September 2008


Aim To assess the risk of myocardial infarction (MI) as a result of hormone therapy (HT), with focus on the influence of age, duration of HT, various regimens and routes, progestagen type, and oestrogen dose.

Methods and results All healthy Danish women (n = 698 098, aged 51–69) were followed during 1995–2001. On the basis of a central prescription registry, daily updated national capture on HT was determined. National Registers identified 4947 MI incidents. Poisson regression analyses estimated rate ratios (RRs). Overall, we found no increased risk [RR 1.03 (95% CI: 0.95–1.11)] of MI with the current HT compared with women who never used HT; age-stratified RR among women aged 51–54, 55–59, 60–64, and 65–69 years were 1.24 (1.02–1.51), 0.96 (0.82–1.12), 1.11 (0.97–1.27), and 0.92 (0.80–1.06), respectively. An increasing risk with longer duration was found for younger women, which was not observed with older age groups. In all age groups, the highest risk of MI was found with continuous HT regimen. No increased risk was found with unopposed oestrogen, cyclic combined therapy, or tibolone. Significantly lower risk was found with dermal route than oral unopposed oestrogen therapy (P = 0.04). No associations were found with progestagen type or oestrogen dose.

Conclusion In a National cohort study, we found that HT regimen and route of application could modify the influence of HT on the risk of MI.

  • Hormone therapy
  • Hormone replacement therapy
  • Myocardial infarction
  • Coronary heart disease
  • Ischaemic heart disease
  • Oestrogen
    View Full Text